Enhertu Shows Promise in Frontline HER2-Mutated NSCLC Treatment
核心洞察
Fam-trastuzumab deruxtecan-nxki (Enhertu) is under investigation as a first-line treatment for HER2 (搜索)-mutated and -overexpressing non-small cell lung cancer (NSCLC (搜索)).
The DESTINY-Lung01 trial revealed a 55% objective response rate and a median progression-free survival of 8.2 months in HER2 (搜索)-mutated NSCLC (搜索) patients.
Combining ADCs with other agents like immunotherapy or chemoimmunotherapy is being explored, with ongoing trials monitoring overlapping toxicities like cytopenia and ILD.
Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) is being evaluated as a frontline treatment for HER2 (搜索)-mutated and -overexpressing non-small cell lung cancer (NSCLC (搜索)), showing promising results in previously treated patients. This development may change the treatment landscape for this subset of lung cancer patients.
DESTINY-Lung01 Trial Results
According to Dr. Noman Ashraf, the phase 2 DESTINY-Lung01 study (NCT03505710) included cohorts of patients with HER2 (搜索) overexpression and HER2 mutations. Both cohorts appeared to benefit from T-DXd, but those with HER2 mutations experienced a confirmed objective response rate (ORR) of 55% and a median progression-free survival of 8.2 months. The median overall survival was 17.8 months.
In patients overexpressing HER2 (搜索) treated with T-DXd at 6.4 mg/kg, the ORR was 26.5%. However, a lower dose of 5.4 mg/kg resulted in an ORR of 34.1% with reduced toxicity. The FDA approved the lower dose of 5.4 mg/kg in 2022.
Moving ADCs to the Frontline Setting
Dr. Ashraf noted that while the DESTINY-Lung01 and DESTINY-Lung02 trials (NCT04644237) administered T-DXd in the second-line setting and beyond, ADCs are now being investigated for upfront treatment in HER2 (搜索)-overexpressed or HER2-mutated diseases.
Combining ADCs with Other Agents
Several studies are exploring the combination of T-DXd with standard-of-care treatments. The phase 2 DESTINY-Lung05 trial (NCT05246514) is examining frontline T-DXd in combination with immunotherapy or chemoimmunotherapy.
Combining drugs requires careful monitoring for overlapping toxicities. ADCs can cause cytopenia, similar to chemotherapy. Additionally, while chemotherapy itself doesn't typically cause interstitial lung disease (ILD), immunotherapy can cause pneumonitis, potentially increasing the risk of ILD when combined with ADCs.
Data from the phase 2 NeoCOAST-2 trial (NCT05061550), presented at the 2024 IASLC World Conference on Lung Cancer, suggests that combining some ADCs with chemotherapy is safe. Although this trial focused on TROP2-targeted ADCs, it indicates the potential for safely combining ADCs with other treatments. More studies are needed to confirm these findings.
The Future of ADCs in NSCLC
ADCs are making significant progress in NSCLC (搜索), with HER2 (搜索) becoming an important target. Both HER2 mutations and overexpression are being addressed, and effective TKIs are also emerging. As research progresses, more ADCs are expected to become available, potentially transforming treatment in both second-line and first-line settings.